Denosumab treatment for osteoporosis appears more hazardous in postmenopausal women with advanced chronic kidney disease (CKD).

USA: A target trial emulation study revealed that denosumab significantly increased the risk of hypocalcemia requiring ...

Type 2 diabetes (T2D) and obesity (OB) are associated with chronic low-grade inflammation and increased fracture risk. In vitro studies showed that inflammation induces bone erosion and inhibits bone ...

The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and ...

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with ...

For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases ...

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

An analysis of pancreatic cancer data in younger adults found that while there is an increasing incidence of pancreatic cancer in young adults, the mortality rate remains stable.

In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as compared with bisphosphonates among women with osteoporosis in the ...